Publications

BibTex format

@article{Frampton:2018:10.18632/oncotarget.24873,
author = {Frampton, AE and Mato, Prado M and Lopez, Jimenez ME and Fajardo, Puerta AB and Jawad, ZR and Lawton, P and Giovannetti, E and Habib, N and Castellano, L and Stebbing, J and Krell, J and Jiao, L},
doi = {10.18632/oncotarget.24873},
journal = {Oncotarget},
pages = {19006--19013},
title = {Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden},
url = {http://dx.doi.org/10.18632/oncotarget.24873},
volume = {9},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Glypican-1 (GPC1) is expressed in pancreatic ductal adenocarcinoma (PDAC) cells and adjacent stroma fibroblasts. Recently, GPC1 circulating exosomes (crExos) have been shown to be able to detect early stages of PDAC. This study investigated the usefulness of crExos GPC1 as a biomarker for PDAC.Methods: Plasma was obtained from patients with benign pancreatic disease (n = 16) and PDAC (n = 27) prior to pancreatectomy, and crExos were isolated by ultra-centrifugation. Protein was extracted from surgical specimens (adjacent normal pancreas, n = 13; and PDAC, n = 17). GPC1 levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: There was no significant difference in GPC1 levels between normal pancreas  and  PDAC  tissues.  This  was  also  true  when  comparing  matched  pairs.  However, GPC1 levels were enriched in PDAC crExos (n = 11), compared to the source tumors (n = 11; 97 ± 54 vs. 20.9 ± 12.3 pg/mL; P < 0.001). In addition, PDACs with high GPC1 expression tended to have crExos with high GPC1 levels. Despite these findings, we were unable to distinguish PDAC from benign pancreatic disease using crExos GPC1 levels. Interestingly, we found that in matched pre and post-operative plasma samples there was a significant drop in crExos GPC1 levels after surgical resection for PDAC (n = 11 vs. 11; 97 ± 54 vs. 77.8 ± 32.4 pg/mL; P = 0.0428). Furthermore, we found that patients with high crExos GPC1 levels have significantly larger PDACs (>4 cm; P = 0.012). Conclusions:  High  GPC1  crExos  may  be  able  to  determine  PDAC  tumor  size  and disease burden. However, further efforts are needed to elucidate its role as a diagnostic and/or prognostic biomarker using larger cohorts of PDAC patients.
AU  - Frampton,AE
AU  - Mato,Prado M
AU  - Lopez,Jimenez ME
AU  - Fajardo,Puerta AB
AU  - Jawad,ZR
AU  - Lawton,P
AU  - Giovannetti,E
AU  - Habib,N
AU  - Castellano,L
AU  - Stebbing,J
AU  - Krell,J
AU  - Jiao,L
DO  - 10.18632/oncotarget.24873
EP  - 19013
PY  - 2018///
SN  - 1949-2553
SP  - 19006
TI  - Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden
T2  - Oncotarget
UR  - http://dx.doi.org/10.18632/oncotarget.24873
UR  - http://hdl.handle.net/10044/1/57827
VL  - 9
ER  -

Download

DrLeandroCastellano

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)